The Long Run with Luke Timmerman
The Long Run with Luke Timmerman is a biotech podcast hosted by Luke Timmerman, founder of the Timmerman Report. It features in-depth conversations with biotech newsmakers and scientific entrepreneurs who are working on transformative therapies and innovations. The show draws parallels between the challenges of scientific discovery and historic expeditions like Ernest Shackleton's Antarctic journey. Guests discuss the stamina, resilience, and determination required to bring new medicines to patients. The podcast explores the evolving relationship between biotechnology and society, offering thought-provoking insights into the future of medicine.
Episodes
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.
Ep203: Sri Kosuri on Small Molecule Correctors of Disease
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.
Ep202: Becky Pferdehirt on Reimagining Science for the AI Era
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
Ep201: Jeremy Levin on Biotech in the Balance
Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."
Ep200: Richard Pops Reflects on a 35-Year Career in Biotech
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.
Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
Ep196: Otello Stampacchia on Europe's Biotech Crisis
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.
Ep192: Kate Haviland on Following the Science to Precision Immunology
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
Ep190: Neil Kumar on Building a Rare Disease Drug Company
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.
Ep188: Art Krieg on Innate Immune System Activators for Cancer
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Ep187: Eric Fischer on Creating a New Class of Medicines
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.
Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope
Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.
Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale
Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.
Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies
Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.
Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors
Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.
Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science
Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.
Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer
Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.
Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA
John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.
Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes
Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.
Ep178: Peyton Greenside on ML-Guided Biologics Discovery
Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.
Ep177: Kevin Parker on Finding Cancer Drug Targets
Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.
Ep176: David Roblin on Building a TechBio Company
David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.
Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.
Ep174: Najat Khan on the TechBio Movement
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
Ep171: Ram Aiyar on RNA Editing Medicines
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
Ep170: David Schenkein on Investing in the Future of Biotech
David Schenkein, general partner at GV, on investing in the future of biotech.
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
Ep167: Leslie Williams on transfer RNA therapies
Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.
Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity
Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.
Ep165: Zach Hornby on Tackling Cancer Drug Resistance
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.
Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients
Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.
Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases
Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.
Ep162: Sean McClain on AI for Biologic Drug Discovery
Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.
Ep161: Jeff Stein on a Long-Lasting Flu Drug
Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.
Ep160: Abe Ceesay on Precision Neuroscience
Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.
Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell Disease
Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.
Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.
Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery
Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.
Ep156: David Liu on New Tools and Techniques for Biology
David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.
Ep155: Valerie Daggett on Early Detection, and Treatment, of Alzheimer's
Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.
Ep154: Robert Ang on CRISPR to Protect Bone Marrow & Attack Cancer
Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.
Ep153: Rick Young on Studying Gene Expression for Drug Discovery
Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.
Ep152: Jens Eckstein on Investing in Healthy Aging
Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.
Ep151: Shelley Force Aldred and Nathan Trinklein on Bispecific Antibodies for Cancer
Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.
Ep150: Jeff Jonker on the Small Molecule Drug Discovery Renaissance
Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.
Ep149: Nancy Stagliano on Precision Neuroscience
Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.
Ep148: Diana Brainard on the Fight Against Infectious Disease
Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.
Ep147: Reid Huber on Investing in the Future of Medicine
Reid Huber, partner at Third Rock Ventures, on investing in the future of medicine.
Ep146: Jeff Huber on Life in Tech and Biotech
Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.
Ep145: Lori Lyons-Williams on Targeted Radiopharmaceuticals for Cancer
Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.
Ep144: Turning the Tables, Rob Perez Interviews Me
Turning the Tables, Rob Perez Interviews Me
Ep143: Zach Weinberg and Alexis Borisy on Freeing the Biotech Founders
Zach Weinberg and Alexis Borisy of Curie.Bio on Freeing the Biotech Founders
Ep142: Fred Appelbaum on how 'Living Medicine' Came to Be
Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.
Ep141: Colin Hill on Digging Deep into Data, Finding New Drug Targets
Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.
Ep140: Yung Lie on Supporting Young Scientists with Bold, Brave Ideas
Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.
Ep139: Kevin Conroy on Early Detection of Cancer
Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.
Ep138: Jodie Morrison on Becoming a Biotech CEO
Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.
Ep137: Aaron Ring on Immunotherapy for Cancer & More
Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.
Ep136: Deborah Palestrant on Building Biotech Startups
Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.
Ep135: John Maraganore on Developing a New Class of Medicines
John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.
Ep134: Emile Nuwaysir on In Vivo Gene Editing Therapies
Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.
Ep133: Catherine Stehman-Breen on Epigenetic Editing Therapies
Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.
Ep132: Eric Dobmeier on Treating Kidney Disease
Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.
Ep131: Ryan Watts on Neuroscience Drug R&D
Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
Ep130: David Hallal on a Life in Biotech & the Cell Therapy Wave
David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.
Ep129: Joanne Smith-Farrell on Engineered B-Cell Therapies
Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.
Ep128: Rick Berke on Building a Biotech Journalism Outlet to Last
Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.
Recommended
Exposing Workplace Bullying
Everyday AI Made Simple - AI For Everyday Tasks
FemTech Focus
Not Too Sensitive - Empowering Highly Sensitive People (HSPs) To Own Their Sensitivity
Mother Daughter Relationship Show
Skin Deep MDs with Dr. Mamina Turegano, Dr. Lindsey Zubritsky and Dr. Jenny Liu
girl talk 🎧🫧
Booked, Blonde & Busy w/ Olivia Ponton
LOVE SOMEONE with Delilah
Classical Christian Education
Veritas Vox - The Voice of Classical Christian Education
Enjoy Teaching Again | Elementary, Teacher Burnout, Student Behavior, SEL, Classroom Management
